Key facts
- ClevelandDx’s last known valuation is $285.2M (Oct 2025).
- It has raised $126.1M; the latest was Later Stage VC ($14.4M) in Oct 2025.
- Notable investors include Novo Holdings, Jumpstart Ventures, JobsOhio Ventures, LYFE Capital, Cleveland Clinic Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for ClevelandDx
- ·The full record, as it builds
Funding rounds
No funding rounds for ClevelandDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ClevelandDx
Developer of a blood-based cancer diagnostics platform designed to improve clarity in disease detection. The company offers the IsoPSA test for prostate cancer, built on its IsoClear platform that measures structural differences in proteins, enabling physicians to reduce unnecessary biopsies and better identify high-grade disease risk.
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 2013
- Employees
- 89
- Website
- clevelanddx.com/
- Ownership
- Privately Held (backing)
ClevelandDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ClevelandDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ClevelandDx in its N-PORT filings yet. We sweep new filings monthly.